BMY Rallies 16.2% in Three Months: Buy, Sell or Hold the Stock?
Bristol Myers Squibb Company BMY has delivered a solid performance in recent months. The biotech major's shares have gained 16.2% over the past three months compared with the industry's growth of 6.8%. The stock has also outperformed both the sector and the S&P 500. …
Sharemaestro market context Trend signal active 52 weeks +46.5%